Clinical effect of vestibular rehabilitation on benign paroxysmal positional vertigo
A protocol for systematic review

Wei Liu, MMa, Cheng-Li Pan, MMb, Xi-chun Wang, MMb, Shuang Sun, MMb,∗

Abstract
Background: This study will evaluate the clinical effect of vestibular rehabilitation (VR) on benign paroxysmal positional vertigo (BPPV).
Methods: In this study, we will identify relevant trials on the topic published in MEDLINE, EBASE, Web of Science, Cochrane Library, Scopus, CINAHL, CBM, and CNKI from inception to the present. We will also search conference proceedings, thesis/dissertation, ongoing trials in clinical trial registry, and reference lists of included studies. Two researchers will independently carry out record selection, data extraction, and study quality assessment, respectively. Any disagreement will be arbitrated and solved with the help of a third researcher. If necessary, we will conduct random-effects meta-analysis to pool the effect estimates of included trials determined to be acceptable heterogeneity.
Results: We will summarize the latest evidence to assess the effect of VR for the treatment of patients with BPPV.
Conclusion: The findings of this study will help determine whether or not VR is effective in treating BPPV.
OSF registration: osf.io/k83y5.
Abbreviations: BPPV = benign paroxysmal positional vertigo, VR = vestibular rehabilitation.
Keywords: benign paroxysmal positional vertigo, effect, vestibular rehabilitation

1. Introduction
Vertigo is a very common symptom and reason for primary clinic practice visit.[1–3] It is reported that about 7.4% general adult population experience such disorder in their lifetime.[4,5] This figure increased in the elderly with an obvious female preponderance.[4–6] Of it, benign paroxysmal positional vertigo (BPPV) accounts for most common type of vertigo.[7–10] It occurs in the inner ear because of the changes in position.[9–12] Although standard treatment is applied to manage such disorder, its 1-year recurrence rate is about 20%, and its 4 to 5 year recurrence rate is between 40% and 50%.[13–15] Thus, effective treatments are still urgent to help manage such issue.

Studies suggested that vestibular rehabilitation (VR) can be utilized for the treatment of patients with BPPV.[16–28] However, there is still insufficient evidence-based medicine evidence to support this topic. Thus, this study will systematically and comprehensively investigate the effect of VR for the treatment of BPPV.

2. Methods
2.1. Study registration
This study protocol was registered on OSF (osf.io/k83y5). It follows the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols standards.[29]

2.2. Eligibility criteria for study selection
2.2.1. Type of studies. This study will include all randomized controlled trials on the topic of VR in treating BPPV. We will exclude animal study, case report, case series, review, comment, and uncontrolled study.

2.2.2. Type of participants. This study will include eligible patients of any age who were diagnosed as BPPV, regardless their race, gender, and educational and economic background.

2.2.3. Type of interventions and controls. In the treatment group, all patients received VR as their management. In the control group, there are no limitations to the comparators. However, we will exclude control treatments involved any forms of VR.
## Table 1
Detailed search strategy for MEDLINE.

| Number | Search terms |
|--------|--------------|
| 1      | Benign paroxysmal positional vertigo |
| 2      | Vertigo |
| 3      | Dizziness |
| 4      | Postural balance |
| 5      | Sudden sensation |
| 6      | Spinning |
| 7      | Moving |
| 8      | Unsteadiness |
| 9      | Dizzy |
| 10     | Or 1–9 |
| 11     | Vestibular rehabilitation |
| 12     | Physical therapy |
| 13     | Physical modality |
| 14     | Physical treatment |
| 15     | Physical management |
| 16     | Or 11–15 |
| 17     | Randomized |
| 18     | Randomly |
| 19     | Random |
| 20     | Blind |
| 21     | Concealment |
| 22     | Allocation |
| 23     | Controlled trial |
| 24     | Clinical trial |
| 25     | Control |
| 26     | Comparator |
| 27     | Trial |
| 28     | Study |
| 29     | Or 17–28 |
| 30     | 10 and 16 and 29 |

### 2.2.4. Type of outcomes.
Outcomes include annual recurrence rate, vertigo intensity, vertigo symptoms, vestibular disability, time to recovery, mean blood velocity (Vm), health-related quality of life, and adverse events.

### 2.3. Search strategy
To examine relevant trials on the topic, this study will search records in MEDLINE, EBASE, Web of Science, Cochrane Library, Scopus, CINAHL, CBM, and CNKI from the beginning to the present. We will not impose any limitation to the language and time of publication. The sample of detailed search strategy for MEDLINE is summarized in Table 1. We will also adapt similar search strategy to the other electronic databases. In addition, we will examine conference proceedings, thesis/dissertation, ongoing trials in clinical trial registry, and reference lists of included studies.

### 2.4. Literature selection and data extraction
#### 2.4.1. Literature selection.
Two researchers will independently scan all identified, and all duplicated citations will be removed. There are 2 stages in the citation selection. First, we will examine all titles/abstracts of all potential records to eliminate all irrelevant studies. Second, full text of the rest articles will be carefully read against all inclusion criteria. If any discrepancy occurs, we will invite a third researcher to resolve it through discussion and a final decision will be made after discussion. The results of study selection will be presented in a flow diagram.

#### 2.4.2. Data extraction.
Two researchers will independently carry out data extraction using previously designed data collection template. The extracted information consists of title, authors, year of publication, country, patient characteristics, diagnostic criteria, inclusion and exclusion criteria, trial design, trial setting, sample size calculation, details of VR and controls, outcomes, follow-up information, dropouts, finding details, and any other relevant information. Any division will be resolved by another experienced researcher through discussion. If we identify any unclear or insufficient or missing data, we will contact primary authors to obtain it through email or fax. If we can not achieve that data, we will only analyze available data, and will discuss its potential impacts to the study findings.

### 2.5. Study quality assessment
Two researchers will independently appraise study quality of all included trials through 7 aspects using Cochrane Risk of Bias Tool. Each filed is further rated as low risk of bias, unclear risk of bias, and high risk of bias. Any division will be resolved by a third researcher via consultation.

### 2.6. Statistical analysis
This study will undertake statistical analysis using RevMan 5.3 software. All continuous outcomes will be estimated as mean difference and 95% confidence intervals. All dichotomous outcome will be calculated as risk ratio and 95% confidence intervals. Statistical heterogeneity across trials will be quantified using $I^2$ test. $I^2 \leq 50\%$ means acceptable heterogeneity, while $I^2 > 50\%$ suggests significant heterogeneity. If there is acceptable heterogeneity, and sufficient data is extracted on the same outcome, we will carry out a random-effects meta-analysis according to the sufficient similarity in study information, patient characteristics, and details of VR and controls. If there is remarkable heterogeneity, we will carry out subgroup analysis to explore its any potential cause. If meta-analysis can not be conducted, we will construct tables to narratively describe and summarize the study findings.

### 2.7. Subgroup analysis
This study will organize a subgroup analysis to explore any possible factors that may result in obvious heterogeneity.

### 2.8. Sensitivity analysis
This study will carry out sensitivity analysis to examine the robustness of study findings by removing low quality studies.

### 2.9. Reporting bias
If more than 10 randomized controlled trials are included in this study, we will detect its reporting bias using Egger regression test[30,31] to check funnel plot asymmetry.

### 2.10. Ethics and dissemination
This study does not require ethical approval, since no individual data will be collected. We plan to disseminate this study on a peer-reviewed journal or via conference meeting.
3. Discussion

Previous studies suggested that VR can be utilized for the treatment of BPPV. However, there is still insufficient evidence to support this topic. With the rising number of clinical trials reporting the effect of VR for BPPV, it is very necessary to pool the outcome data from eligible trials to accurately appraise its treatment effect. We will search both electronic databases and other resources to avoid missing potential trials. Then, we will incorporate outcome data from different trials into analyses. The findings of this study may provide evidence to support the effect of VR for the treatment of BPPV. However, this study still has several drawbacks. First, there may be insufficient number of eligible trials. Second, the sample size of included trials may be small. Third, the methodological quality of included studies may be poor. Fourth, the statistical heterogeneity of pooled outcomes may be remarkable. All those limitations may affect the findings of this study.

Author contributions

Conceptualization: Wei Liu, Xi-chun Wang, Shuang Sun. Data curation: Wei Liu, Cheng-Li Pan. Formal analysis: Wei Liu, Cheng-Li Pan, Xi-chun Wang, Shuang Sun. Investigation: Shuang Sun. Methodology: Wei Liu, Xi-chun Wang. Project administration: Shuang Sun. Resources: Wei Liu, Cheng-Li Pan. Software: Cheng-Li Pan, Xi-chun Wang. Supervision: Shuang Sun. Validation: Wei Liu, Cheng-Li Pan, Xi-chun Wang, Shuang Sun. Visualization: Xi-chun Wang, Shuang Sun. Writing – original draft: Wei Liu, Cheng-Li Pan, Xi-chun Wang, Shuang Sun. Writing – review & editing: Wei Liu, Cheng-Li Pan, Shuang Sun.

References

[1] Handschu R, Tauber A, Schuh A. Chronic vertigo. MMW Fortschr Med 2019;161:45–52.
[2] Walther LE. Current diagnostic procedures for diagnosing vertigo and dizziness. GMS Curr Top Otorhinolaryngol Head Neck Surg 2017;16:2.
[3] Walther LE, Błędow A. Current aspects of vertigo and dizziness in advanced age. HNO 2020;68:191–8.
[4] Neuhauser HK, von Bevern M, Radtke A, et al. Epidemiology of vestibular vertigo: a neurologic survey of the general population. Neurology 2005;65:898–904.
[5] Neuhauser HK, Lempert T. Vertigo: epidemiologic aspects. Semin Neurol 2009;29:473–81.
[6] Uhl B, Biber F, I. Vertigo and ageing - essentials for general practice. MMW Fortschr Med 2019;161:41–5.
[7] Chen G, Dai X, Ren X, et al. Ocular vs cervical vestibular evoked myogenic potentials in benign paroxysmal positional vertigo: a systematic review and meta-analysis. Front Neurol 2020;11:596434.
[8] Oh SR, Min SJ, Kim GE, et al. The effects of climate on the incidence of benign paroxysmal positional vertigo. Int J Biometeorol 2020;64:2119–25.
[9] Pedersen MF, Erikson HH, Kjaersgaard JB, et al. Treatment of benign paroxysmal positional vertigo with the TRV reposition chair. J Int Adv Otol 2020;16:176–82.
[10] Li S, Wang Z, Liu Y, et al. Risk factors for the recurrence of benign paroxysmal positional vertigo: a systematic review and meta-analysis. Ear Nose Throat J 2020;145:61320943362.
[11] Yu J, Yu Q, Guan B, et al. Pseudo-benign paroxysmal positional vertigo: a retrospective study and case report. Front Neurol 2020;11:187.
[12] Yetser S. Review of the pathology underlying benign paroxysmal positional vertigo. J Int Med Res 2020;48:300060519892370.
[13] Tanimoto H, Doi K, Nishikawa T, et al. Risk factors for recurrence of benign paroxysmal positional vertigo. J Otolaryngol Head Neck Surg 2008;37:832–5.
[14] Sakaida M, Takeuchi K, Shinagawa H, et al. Long-term outcome of benign paroxysmal positional vertigo. Neurology 2003;60:1532–4.
[15] Brandt T, Huppert D, Hecht J, et al. Benign paroxysmal positioning vertigo: a long-term follow-up (6-17 years) of 125 patients. Acta Otolaryngol 2006;126:160–3.
[16] Zou TM, Chen JM, Zhou XW, et al. The curative effect of manual reduction combined with vestibular rehabilitation exercise in the treatment of benign paroxysmal positional vertigo. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2019;33:1044–8.
[17] Wu P, Cao W, Hu Y, et al. Effects of vestibular rehabilitation, with or without betahistine, on managing residual dizziness after successful repositioning manoeuvres in patients with benign paroxysmal positional vertigo: a protocol for a randomised controlled trial. BMJ Open 2019;9:e026711.
[18] Male AJ, Ramdharry GM, Grant R, et al. A survey of current management of Benign Paroxysmal Positional Vertigo (BPPV) by physiotherapists’ interested in vestibular rehabilitation in the UK. Physiotherapy 2019;105:307–14.
[19] Sun LB, Zheng ZY, Wang BQ, et al. Curative effect analysis of the vestibular rehabilitation training on residual dizziness after successful canalith repositioning manoeuvres in patients with benign paroxysmal positional vertigo. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2017;31:897–900.
[20] Ribeiro KF, Oliveira BS, Freitas RV, et al. Effectiveness of otolith repositioning maneuvers and vestibular rehabilitation exercises in elderly people with benign paroxysmal positional vertigo: a systematic review. Braz J Otorhinolaryngol 2017;83:108–14.
[21] Bressi F, Vella P, Casale M, et al. Vestibular rehabilitation in benign paroxysmal positional vertigo: reality or fiction? Int J Immunopathol Pharmacol 2017;30:113–22.
[22] Ribeiro KM, Ferreira LM, Freitas RV, et al. Positive to Negative” Dix-Hallpike test and Benign Paroxysmal Positional Vertigo recurrence in elderly undergoing Canalith Repositioning Maneuver and Vestibular Rehabilitation. Int Arch Otorhinolaryngol 2016;20:344–52.
[23] Ribeiro KM, Freitas RV, Ferreira LM, et al. Effects of balance Vestibular Rehabilitation Therapy in elderly with Benign Paroxysmal Positional Vertigo: a randomized controlled trial. Disabil Rehabil 2017;39:1198–206.
[24] van der Scheer-Horst ES, van Bentheim PP, Bruintjes TD, et al. The efficacy of vestibular rehabilitation in patients with benign paroxysmal positional vertigo: a rapid review. Otolaryngol Head Neck Surg 2014;151:740–5.
[25] Wegner I, Niessen ME, van Werkhoven CH, et al. Rapid systematic review of the epley maneuver versus vestibular rehabilitation for benign paroxysmal positional vertigo. Otolaryngol Head Neck Surg 2014;151:201–7.
[26] Schoter DD, Schoter JA, Azzi VJ. Evaluation of quality of life pre- and post-vestibular rehabilitation in patients with benign paroxysmal positional vertigo associated with Meniere’s disease. Int Arch Otorhinolaryngol 2012;16:430–6.
[27] Van Garcia F. Treatment failures in benign paroxysmal positional vertigo. Role of vestibular rehabilitation. Rev Laryngol Otol Rhinol (Bord) 2005;126:271–4.
[28] Herdman SJ, Blatt PJ, Schubert MC. Vestibular rehabilitation of patients with vestibular hypofunction or with benign paroxysmal positional vertigo. Curr Opin Neurol 2000;13:39–43.
[29] Shamsaei L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;350:g7647.
[30] Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000;320:1574–7.
[31] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.